Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117583 | 0.85 | DRD2 (0.55) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL7120429 | 0.83 | DRD2 (0.52) | DRD2HTR2AHTR1ADRD3KCNH2 | |
| SCHEMBL7127121 | 0.80 | HTR1A (0.52) | DRD2HTR1A | |
| SCHEMBL7121850 | 0.79 | HTR2A (0.56) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL7118961 | 0.78 | HTR2A (0.55) | DRD2HTR2AHTR1AHTR7KCNH2 | |
| SCHEMBL7120413 | 0.76 | HTR1A (0.53) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL7128893 | 0.76 | HTR2A (0.55) | DRD2HTR2AHTR1AHTR7KCNH2 | |
| SCHEMBL7122142 | 0.76 | HTR2A (0.54) | DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL7119229 | 0.75 | HTR2A (0.58) | DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL7119957 | 0.74 | DRD2 (0.50) | DRD2HTR2AHTR1ADRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | claimed |
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | disclosed |
| EP-1246820-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049683-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | CRBN, CDR2, DRD3 | DRD2 7/4885HTR2A 176/4885HTR1A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.